Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Human induced pluripotent stem cells (iPSCs) represent a unique opportunity for regenerative medicine because they offer the prospect of generating unlimited quantities of cells for autologous transplantation, with potential application in treatments for a broad range of disorders. However, the use of human iPSCs in the context of genetically inherited human disease will require the correction of disease-causing mutations in a manner that is fully compatible with clinical applications. The methods currently available, such as homologous recombination, lack the necessary efficiency and also leave residual sequences in the targeted genome. Therefore, the development of new approaches to edit the mammalian genome is a prerequisite to delivering the clinical promise of human iPSCs. Here we show that a combination of zinc finger nucleases (ZFNs) and piggyBac technology in human iPSCs can achieve biallelic correction of a point mutation (Glu342Lys) in the α1-antitrypsin (A1AT, also known as SERPINA1) gene that is responsible for α1-antitrypsin deficiency. Genetic correction of human iPSCs restored the structure and function of A1AT in subsequently derived liver cells in vitro and in vivo. This approach is significantly more efficient than any other gene-targeting technology that is currently available and crucially prevents contamination of the host genome with residual non-human sequences. Our results provide the first proof of principle, to our knowledge, for the potential of combining human iPSCs with genetic correction to generate clinically relevant cells for autologous cell-based therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
A map of human genome variation from population-scale sequencing.
The 1000 Genomes Project Consortium (2010) · Nature · doi:10.1038/nature09534 · Cited by 7,877
Genome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
Self-citationZinc Finger-DNA Recognition: Crystal Structure of a Zif268-DNA Complex at 2.1 Å
Pavletich, N. P., & Pabo, C. O. (1991) · Science · doi:10.1126/science.2028256 · Cited by 2,061
A ROCK inhibitor permits survival of dissociated human embryonic stem cells
Watanabe, K., Ueno, M., Kamiya, D., Nishiyama, A., Matsumura, M., Wataya, T., Takahashi, J. B., Nishikawa, S., Nishikawa, S.-I., Muguruma, K., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1310 · Cited by 2,055
A conditional knockout resource for the genome-wide study of mouse gene function
Skarnes, W. C., Rosen, B., West, A. P., Koutsourakis, M., Bushell, W., Iyer, V., Mujica, A. O., Thomas, M., Harrow, J., Cox, T., et al. (2011) · Nature · doi:10.1038/nature10163 · Cited by 1,708
Self-citationHighly efficient endogenous human gene correction using designed zinc-finger nucleases
Urnov, F. D., Miller, J. C., Lee, Y.-L., Beausejour, C. M., Rock, J. M., Augustus, S., Jamieson, A. C., Porteus, M. H., Gregory, P. D., & Holmes, M. C. (2005) · Nature · doi:10.1038/nature03556 · Cited by 1,641
Self-citationFUSAKI, N., BAN, H., NISHIYAMA, A., SAEKI, K., & HASEGAWA, M. (2009) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.85.348 · Cited by 1,411
Self-citationTreatment of sickle cell anemia mouse model with iPS cells generated from autologous skin
Hanna, J., Wernig, M., Markoulaki, S., Sun, C.-W., Meissner, A., Cassady, J. P., Beard, C., Brambrink, T., Wu, L.-C., Townes, T. M., et al. (2007) · Science · doi:10.1126/science.1152092 · Cited by 1,202
Cited by
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
Gaj, T., Gersbach, C. A., & Barbas, C. F. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.04.004 · Cited by 3,820
TALENs: A widely applicable technology for targeted genome editing
Joung, J. K., & Sander, J. D. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3486 · Cited by 1,650
“…studies have shown that ZFN-induced HDR can be used to correct genetic mutations responsible for sickle cell anemia 72 or alpha1-antitypsin disease 73 or in the Parkinson’s disease-associated alpha-synuclein gene 74 in patient-specific induced pluripotent stem cells that have been reprogrammed…”
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
A guide to genome engineering with programmable nucleases
Kim, H., & Kim, J.-S. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3686 · Cited by 1,163
Genome-editing Technologies for Gene and Cell Therapy
Maeder, M. L., & Gersbach, C. A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.10 · Cited by 719
CRISPR/Cas9 for genome editing: progress, implications and challenges
Zhang, F., Wen, Y., & Guo, X. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu125 · Cited by 683
GDF15 mediates the effects of metformin on body weight and energy balance
Coll, A. P., Chen, M., Taskar, P., Rimmington, D., Patel, S., Tadross, J. A., Cimino, I., Yang, M., Welsh, P., Virtue, S., et al. (2020) · Nature · doi:10.1038/s41586-019-1911-y · Cited by 584
Self-citationStem/progenitor cells in liver development, homeostasis, regeneration, and reprogramming
Miyajima, A., Tanaka, M., & Itoh, T. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.04.010 · Cited by 570
Genome Engineering with Targetable Nucleases
Carroll, D. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060713-035418 · Cited by 568
“Only a single off-target exon mutation was introduced upon ZFN treatment, although 25 mutations accumulated during the initial derivation of the iPS cells (233).”
BackgroundModeling mouse and human development using organoid cultures
Huch, M., & Koo, B.-K. (2015) · Development · doi:10.1242/dev.118570 · Cited by 539
Ring, K. L., Tong, L. M., Balestra, M. E., Javier, R., Andrews-Zwilling, Y., Li, G., Walker, D., Zhang, W. R., Kreitzer, A. C., & Huang, Y. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.018 · Cited by 538
Induced Pluripotent Stem Cells Meet Genome Editing
Hockemeyer, D., & Jaenisch, R. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.04.013 · Cited by 499
“Independent proof of concept studies demonstrated that SSNs can be used to repair or introduce disease relevant mutations in hPSCs (Soldner et al., 2011; Yusa et al., 2011).”
BackgroundLung regeneration: mechanisms, applications and emerging stem cell populations
Kotton, D. N., & Morrisey, E. E. (2014) · Nature Medicine · doi:10.1038/nm.3642 · Cited by 515
Alpha 1 -Antitrypsin Deficiency
Strnad, P., McElvaney, N. G., & Lomas, D. A. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1910234 · Cited by 515
Self-citationGenetics of Human Cardiovascular Disease
Kathiresan, S., & Srivastava, D. (2012) · Cell · doi:10.1016/j.cell.2012.03.001 · Cited by 496
Veres, A., Gosis, B. S., Ding, Q., Collins, R., Ragavendran, A., Brand, H., Erdin, S., Cowan, C. A., Talkowski, M. E., & Musunuru, K. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.04.020 · Cited by 474
“Previous studies have documented mutagenesis occurring during the derivation and expansion of hPSCs (Hussein et al., 2011; Gore et al., 2011; Howden et al., 2011; Yusa et al., 2011).”
Induced pluripotent stem cells: the new patient?
Bellin, M., Marchetto, M. C., Gage, F. H., & Mummery, C. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3448 · Cited by 431
Loh, K. M., Ang, L. T., Zhang, J., Kumar, V., Ang, J., Auyeong, J. Q., Lee, K. L., Choo, S. H., Lim, C. Y. Y., Nichane, M., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2013.12.007 · Cited by 418
The SMAD2/3 interactome reveals that TGFβ controls m6A mRNA methylation in pluripotency
Bertero, A., Brown, S., Madrigal, P., Osnato, A., Ortmann, D., Yiangou, L., Kadiwala, J., Hubner, N. C., de los Mozos, I. R., Sadée, C., et al. (2018) · Nature · doi:10.1038/nature25784 · Cited by 378
Self-citationGenetic Correction of Huntington's Disease Phenotypes in Induced Pluripotent Stem Cells
An, M. C., Zhang, N., Scott, G., Montoro, D., Wittkop, T., Mooney, S., Melov, S., & Ellerby, L. M. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.04.026 · Cited by 376
Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development
Karagiannis, P., Takahashi, K., Saito, M., Yoshida, Y., Okita, K., Watanabe, A., Inoue, H., Yamashita, J. K., Todani, M., Nakagawa, M., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00039.2017 · Cited by 368
Wilgenburg, B. V., Browne, C., Vowles, J., & Cowley, S. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071098 · Cited by 353
Production of hepatocyte-like cells from human pluripotent stem cells
Hannan, N. R. F., Segeritz, C.-P., Touboul, T., & Vallier, L. (2013) · Nature Protocols · doi:10.1038/nprot.2012.153 · Cited by 338
Self-citationOrigins of Programmable Nucleases for Genome Engineering
Chandrasegaran, S., & Carroll, D. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.10.014 · Cited by 325
Cell therapy for liver disease: From liver transplantation to cell factory
Forbes, S. J., Gupta, S., & Dhawan, A. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.040 · Cited by 325
Greene, C. M., Marciniak, S. J., Teckman, J., Ferrarotti, I., Brantly, M. L., Lomas, D. A., Stoller, J. K., & McElvaney, N. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.51 · Cited by 324
Self-citationYe, L., Wang, J., Beyer, A. I., Teque, F., Cradick, T. J., Qi, Z., Chang, J. C., Bao, G., Muench, M. O., Yu, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407473111 · Cited by 320
Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids
Marsee, A., Roos, F. J. M., Verstegen, M. M. A., Marsee, A., Roos, F., Verstegen, M., Clevers, H., Vallier, L., Takebe, T., Huch, M., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.04.005 · Cited by 310
Self-citationCell and tissue engineering for liver disease
Bhatia, S. N., Underhill, G. H., Zaret, K. S., & Fox, I. J. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3005975 · Cited by 309
A genetically encoded sensor for measuring serotonin dynamics
Wan, J., Peng, W., Li, X., Qian, T., Song, K., Zeng, J., Deng, F., Hao, S., Feng, J., Zhang, P., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00823-7 · Cited by 302
Denning, C., Borgdorff, V., Crutchley, J., Firth, K. S. A., George, V., Kalra, S., Kondrashov, A., Hoang, M. D., Mosqueira, D., Patel, A., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.10.014 · Cited by 293
Isolation of single-base genome-edited human iPS cells without antibiotic selection
Miyaoka, Y., Chan, A. H., Judge, L. M., Yoo, J., Huang, M., Nguyen, T. D., Lizarraga, P. P., So, P.-L., & Conklin, B. R. (2014) · Nature Methods · doi:10.1038/nmeth.2840 · Cited by 301
Devlin, A.-C., Burr, K., Borooah, S., Foster, J. D., Cleary, E. M., Geti, I., Vallier, L., Shaw, C. E., Chandran, S., & Miles, G. B. (2015) · Nature Communications · doi:10.1038/ncomms6999 · Cited by 295
Self-citationInterspecies organogenesis generates autologous functional islets
Yamaguchi, T., Sato, H., Kato-Itoh, M., Goto, T., Hara, H., Sanbo, M., Mizuno, N., Kobayashi, T., Yanagida, A., Umino, A., et al. (2017) · Nature · doi:10.1038/nature21070 · Cited by 283
Self-citationShlomai, A., Schwartz, R. E., Ramanan, V., Bhatta, A., de Jong, Y. P., Bhatia, S. N., & Rice, C. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412631111 · Cited by 258
Itoh, M., Umegaki-Arao, N., Guo, Z., Liu, L., Higgins, C. A., & Christiano, A. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077673 · Cited by 239
“These authors also confirmed that genetic correction in human iPSCs restored the structure and function of α1-antitrypsin in subsequently derived liver-like cells [29], indicating that the combination of a genome editing technique such as ZFNs, and more recently transcription activator-like effector nucleases (TALENs)…”
BackgroundMaetzel, D., Sarkar, S., Wang, H., Abi-Mosleh, L., Xu, P., Cheng, A. W., Gao, Q., Mitalipova, M., & Jaenisch, R. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.03.014 · Cited by 195
“containing a puromycin selection cassette (PGK-puroDtk-pGHpA cassette) flanked by piggyBac terminal repeats (Yusa et al., 2011).”
BackgroundMethodInfluentialPark, C.-Y., Halevy, T., Lee, D. R., Sung, J. J., Lee, J. S., Yanuka, O., Benvenisty, N., & Kim, D.-W. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.084 · Cited by 178
“During the last several years, correction of genetic defects using programmed nucleases has been attempted for several genetic diseases (Yusa et al., 2011; Sebastiano et al., 2011; Yin et al., 2014; Long et al., 2014; Maetzel et al., 2014; Li et al., 2015).”
BackgroundSuzuki, K., Yu, C., Qu, J., Li, M., Yao, X., Yuan, T., Goebl, A., Tang, S., Ren, R., Aizawa, E., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.06.016 · Cited by 169
Araki, M., & Ishii, T. (2014) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-12-108 · Cited by 150
“Moreover, gene corrections by ZFNs have been reported regarding induced pluripotent stem cells derived somatic cells biopsied from patients with sickle cell disease, alpha1-antitrypsin deficiency, and Parkinson’s disease [27-30].”
BackgroundSingle-cell atlas of human liver development reveals pathways directing hepatic cell fates
Wesley, B. T., Ross, A. D. B., Muraro, D., Miao, Z., Saxton, S., Tomaz, R. A., Morell, C. M., Ridley, K., Zacharis, E. D., Petrus-Reurer, S., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00989-7 · Cited by 146
Self-citationConversion of human fibroblasts to angioblast-like progenitor cells
Kurian, L., Sancho-Martinez, I., Nivet, E., Aguirre, A., Moon, K., Pendaries, C., Volle-Challier, C., Bono, F., Herbert, J.-M., Pulecio, J., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2255 · Cited by 145
Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN
Ain, Q. U., Chung, J. Y., & Kim, Y.-H. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.036 · Cited by 130
Umegaki-Arao, N., Pasmooij, A. M. G., Itoh, M., Cerise, J. E., Guo, Z., Levy, B., Gostyński, A., Rothman, L. R., Jonkman, M. F., & Christiano, A. M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009342 · Cited by 123
Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases
Trepotec, Z., Lichtenegger, E., Plank, C., Aneja, M. K., & Rudolph, C. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.012 · Cited by 115
Cas9-induced large deletions and small indels are controlled in a convergent fashion
Kosicki, M., Allen, F., Steward, F., Tomberg, K., Pan, Y., & Bradley, A. (2022) · Nature Communications · doi:10.1038/s41467-022-30480-8 · Cited by 115
Self-citationDelivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9
LaFountaine, J. S., Fathe, K., & Smyth, H. D. C. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.08.029 · Cited by 111
Efficient genomic correction methods in human iPS cells using CRISPR–Cas9 system
Li, H. L., Gee, P., Ishida, K., & Hotta, A. (2016) · Methods · doi:10.1016/j.ymeth.2015.10.015 · Cited by 62
Human liver organoids: From generation to applications
Afonso, M. B., Marques, V., van Mil, S. W. C., & Rodrigues, C. M. P. (2024) · Hepatology · doi:10.1097/hep.0000000000000343 · Cited by 61
Potential of human induced pluripotent stem cells in studies of liver disease
Sampaziotis, F., Segeritz, C., & Vallier, L. (2015) · Hepatology · doi:10.1002/hep.27651 · Cited by 49
“13 In a subsequent study, the same group reported rescue of the disease phenotype, 14 following correction of the SERPINA1 mutation using zinc finger nucleases, thereby 15 demonstrating a direct association between the phenotype observed and the 16 underlying genetic defect (35).”
MethodSelf-citationThe road to regenerative liver therapies: the triumphs, trials and tribulations
Raju, R., Chau, D., Verfaillie, C. M., & Hu, W.-S. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.08.022 · Cited by 14
(2022) · doi:10.1093/nar/gkac1191 · Cited by 13
Metadata
- Authors
- Yusa, K., Rashid, S. T., Strick-Marchand, H., Varela, I., Liu, P.-Q., Paschon, D. E., Miranda, E., Ordóñez, A., Hannan, N. R. F., Rouhani, F. J., Darche, S., Alexander, G., Marciniak, S. J., Fusaki, N., Hasegawa, M., Holmes, M. C., Di Santo, J. P., Lomas, D. A., Bradley, A., & Vallier, L.
- Venue
- Nature
- Published
- 2011-10-12
- Volume
- 478
- Issue
- 7369
- Pages
- 391-394
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1984582197
- Cited by
- 639
- References
- 37
- FWCI
- 26.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.